Reticulate Hyperpigmentation secondary to 5-fluorouracil and idarubicin.
Although cutaneous reactions from antineoplastic therapy are common, a reticulate pattern of hyperpigmentation has not been frequently reported in the literature. We report 2 cases of reticulate hyperpigmentation associated with cancer chemotherapy with 5-fluorouracil and idarubicin. These 2 cases serve to raise awareness of this particular pattern of hyperpigmentation as a potential side effect of chemotherapeutic regimens.
Jogi
Reena
R
Department of Dermatology, Baylor College of Medicine, Houston, TX 77030, USA.
Garman
Mary
M
Pielop
Josie
J
Orengo
Ida
I
Hsu
Sylvia
S
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy; D003561:Cytarabine / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced* / Q000473:pathology*; D015255:Idarubicin / Q000009:adverse effects* / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged; D010307:Parotid Neoplasms / Q000150:complications / Q000188:drug therapy; D012867:Skin / Q000473:pathology*
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D005472:Fluorouracil; D015255:Idarubicin